• AusCann is positioned as the only company in the region that has the fully integrated capability to grow and manufacture cannabis medicines in Australia
• Strong progress of operations in Australia with key licences granted for R&D, cultivation and manufacturing
• Appointment of Medical Liaison Managers to lead Medical Outreach program across Australia
• Medical Outreach program well underway with positive feedback and engagement from Australian doctors
• Australian market continues to evolve with positive regulatory advances and growing momentum and support
AusCann Group Holdings Ltd (ASX:AC8 or ‘the Company’) has today announced its appendix 4C for the 3-month period ended 30 September 2017 and is pleased to provide an overview of its activities for the quarter.
To view Report please download PDF attached:
Download this document
